Sarepta Therapeutics Inc [SRPT] stock is trading at $14.07, down -35.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The SRPT shares have lost -22.54% over the last week, with a monthly amount drifted -34.72%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on July 18, 2025, when Needham downgraded its rating to a Hold. Previously, William Blair downgraded its rating to Mkt Perform on June 20, 2025. On June 18, 2025, downgrade downgraded it’s rating to Hold but maintained its price target of $24 on the stock. Wolfe Research started tracking the stock assigning a Peer Perform rating. Piper Sandler downgraded its rating to a Neutral but $36 remained the price target by the analyst firm on June 16, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on June 16, 2025. In a note dated June 16, 2025, H.C. Wainwright downgraded an Sell rating on this stock but restated the target price of $10.
Sarepta Therapeutics Inc [SRPT] stock has fluctuated between $16.88 and $150.48 over the past year. Currently, Wall Street analysts expect the stock to reach $49.17 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $14.07 at the most recent close of the market. An investor can expect a potential return of 249.47% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 2.23B for the trailing twelve months, which represents a growth of 80.15%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.2 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.53 points at the first support level, and at 8.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.90, and for the 2nd resistance point, it is at 21.73.
Ratios To Look Out For
For context, Sarepta Therapeutics Inc’s Current Ratio is 4.02. On the other hand, the Quick Ratio is 2.46, and the Cash Ratio is 0.4. Considering the valuation of this stock, the price to sales ratio is 0.62, the price to book ratio is 1.21.
Transactions by insiders
Recent insider trading involved Nicaise Claude, Director, that happened on Mar 12 ’25 when 2491.0 shares were sold. Director, Nicaise Claude completed a deal on Mar 12 ’25 to buy 2491.0 shares. Meanwhile, Director Wigzell Hans Lennart Rudolf sold 10500.0 shares on Dec 12 ’24.
